Welcome to PharmaDots
Where data is discovered
Introducing PharmaDots, an innovative approach to databases where we transform data from disparate sources using our AI Edge platform.
Our cutting-edge technology produces relevant visualizations and analytics, driving predictive intelligence.
Overview
PharmaDots is a leading AI-powered platform delivering integrated solutions in oncology. Our suite of platforms—ADC Connect, IO Connect, Target Connect, and Tumor Connect—offers:
- Comprehensive tumor landscapes
- Detailed product profiles
- Extensive preclinical and clinical datasets with customizable download options
We transform complex scientific data into clear, actionable insights, empowering faster and more informed decision-making. Every dataset is carefully curated and updated daily, ensuring reliable, ready-to-use competitive intelligence at your fingertips.
With PharmaDots, you can harness the power of intelligent data to gain a strategic edge, streamline research, and accelerate progress toward your goals.
Offers in-depth insights into complex topics such as drug chemistry, MoAs, and granular clinical trial data by patient segments. Tracks preclinical-to-clinical transitions, trial failures, and key deals and partnerships. With daily updates from various secondary sources, trial registries, and oncology conferences, PharmaDots empowers business leaders to make informed, data-driven decisions in oncology.
Our proprietary AI Edge platforms (ADC Connect, IO Connect, Tumor Connect, and Target Connect) deliver expert-validated, real-time insights through automated data integration and visualization with flexible download options.
Vast and disparate datasets across ADCs, IOs, tumors, and targets are seamlessly integrated and transformed into intuitive visualizations and advanced analytics, making complex oncology data clear, actionable, and ready for decision-making.
Our intuitive platform interface (ADC Connect, IO Connect, Tumor Connect, and Target Connect) allows effortless navigation and easy access to data on ADCs, IOs, multiple tumors, and targets. Whether you are a seasoned oncology researcher or a new user from any cross-functional team without prior domain expertise, our platform ensures a seamless user experience
Our platform is equipped with the highest levels of data security and reliability, providing users with confidence in the integrity and reliability of preclinical and clinical data
Our Connect Modules
PharmaDots’ Connect Modules offer unparalleled access to cutting-edge data-driven insights in oncology, delivering an extensive and continuously updated landscape across critical areas such as ADCs, Immuno-Oncology (IO), and 250+ Tumor and Target Landscapes. Our database modules are designed to empower more informed decision-making, supporting therapy area strategies, research, and outcomes.
ADC Connect is your ultimate hub for intelligence on ADCs and next-generation conjugates. You can explore asset chemistry, clinical trial efficacy, toxicities, preclinical/clinical evidences from the latest publications, conferences, and trial registries
IO Connect is your hub for Immuno-Oncology intelligence, covering over 60 MoAs such as Immune Checkpoint Inhibitors, Cell Therapies, Oncolytic Viruses, and Cytokines and many more. It enables seamless tracking of assets from investigational to approved products—giving you a complete view of the IO landscape.
Coming soon
Tumor Connect provides access to 100+ tumor landscapes, updated daily, enabling researchers and strategists to map disease-area insights and support indication prioritization.
Coming soon
Explore 150+ therapeutic targets with Target Connect — unlock deep target intelligence and prioritize high-value strategic opportunities in the oncology space.
Coming soonResources
Stay competitive and informed with our weekly newsletter on commercial, regulatory, and research updates in the Antibody Drug Conjugates (ADCs) space. Designed for industry leaders and professionals, this bulletin delivers essential insights to keep you ahead in this rapidly evolving field.
